Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety. Up to 18 evaluable adult and 18 evaluable pediatric subjects will be enrolled. Evaluable subjects are defined as those who have received an infusion of HG-CT-1. Primary clinical objectives: i. Determine the safety of HG-CT-1 based on the proportion of subjects infused with HG-CT-1 who experience a dose limiting toxicity (DLT). Secondary clinical objectives: i. Estimate the efficacy of HG-CT-1 according to standard clinical response criteria for AML. ii. Estimate overall survival of evaluable subjects. iii. Estimate progression-free survival of evaluable subjects. iv. Estimate duration of response in evaluable subjects who achieve a response. Secondary scientific objectives: i. Describe the persistence and trafficking of HG-CT-1. ii. Describe HG-CT-1 bioactivity and its predictors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej (dzieci od 12 lat, ważące co najmniej 35 kg, mogą być włączone po ocenie bezpieczeństwa u dorosłych)
- •Diagnoza białaczki ostroleukemii (AML), która nie poddaje się dostępnym terapiom
- •Białaczka nowo rozpoznana, która nie odpowiedziała na dwie serie intensywnej chemioterapii
- •Białaczka, która powróciła po przeszczepieniu szpiku kostnego
- •Białaczka, która powróciła w ciągu 12 miesięcy od pierwszego leczenia
- •Białaczka, która powróciła po więcej niż 12 miesiącach, ale nie uległa całkowitej remisji po ponownym leczeniu
- •Białaczka, która powróciła drugi lub więcej razy
- •Potwierdzenie obecności białka FLT3 w komórkach białaczki (badanie przep-ływ cytometrią)
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Last updated (source)
- September 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
MD Anderson
Houston, United States
Trial contact
Nicholas Short
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.